Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.34 |
| ▸ | NPC1 | O15118 | 5/20 | 0.34 |
| ▸ | RAB9A | P51151 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2029895 | 0.88 | LIPG (0.51) | LPLLIPGDGAT1SMN1; SMN2NPC1 | |
| SCHEMBL9959009 | 0.85 | SNCA (0.42) | LPLLIPGDGAT1SMN1; SMN2NPC1 | |
| SCHEMBL25200891 | 0.77 | IRAK4 (0.39) | LPLLIPG | |
| SCHEMBL26906261 | 0.76 | LPL (0.35) | LPLLIPG | |
| SCHEMBL19933806 | 0.73 | MAP4K4 (0.43) | LPLLIPGDGAT1MEN1KMT2A | |
| SCHEMBL26906352 | 0.72 | MAP4K4 (0.41) | LPLLIPGDGAT1 | |
| SCHEMBL22650435 | 0.71 | LPL (0.42) | LPLLIPG | |
| SCHEMBL2030860 | 0.71 | KMT2A (0.41) | SMN1; SMN2NPC1RAB9AKDM4EMEN1 | |
| SCHEMBL1727061 | 0.71 | LIPG (0.47) | LPLLIPGDGAT1SMN1; SMN2NPC1 | |
| SCHEMBL30682135 | 0.71 | PIK3CB (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477990-B1 | 5-PHENYL PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-08-20 | — | — | EP | disclosed |
| EP-2477990-B1 | 5-PHENYL PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-08-20 | — | — | EP | disclosed |
| US-8618301-B2 | 5-phenylpyrazolopyridine derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2013-12-31 | — | — | US | disclosed |
| US-20130023554-A1 | 5-PHENYLPYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-01-24 | — | — | US | disclosed |
| US-20130023554-A1 | 5-PHENYLPYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-01-24 | — | — | US | disclosed |
| US-20130023554-A1 | 5-PHENYLPYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-01-24 | — | — | US | disclosed |
| EP-2477990-A1 | 5-PHENYL PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-07-25 | — | — | EP | disclosed |
| WO-2011033230-A1 | 5-PHENYL PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-24 | — | — | WO | disclosed |
| WO-2011033230-A1 | 5-PHENYL PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023554-A1 | 5-PHENYLPYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | CBR3, CBR1, OGFR | LPL 4298/4885LIPG 4690/4885DGAT1 3923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.